Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 54

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1A
Chunk 54
---
 our information technology systems, or those of third-parties upon which we rely, including cloud-based services, our business operations and financial condition could be adversely affected.

•Artificial intelligence introduces emerging risks and challenges to our business. 

•Each of our tests is processed in a single one of our laboratory facilities, and any loss or prolonged interruption of our ability to use these laboratories or failure to maintain their operation in compliance with applicable regulations would seriously harm our business.

•We depend on a limited number of third parties, or, in some cases, single-source suppliers, for equipment, reagents, other supplies, and specimen collection services. If these supplies or services become unavailable or are disrupted, then we may not be able to successfully perform our research, operate our business, or perform our tests on a timely basis or at all.

•Our international business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States. 

•Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.

•We rely on commercial courier delivery services to transport biological materials to our facilities in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.

•Our financial condition and results of operations could be adversely affected by adverse public health developments.

•We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating results.

•Impairment in the value of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition.

•Our estimates of actionable market size and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at expected rates.

•Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

•Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition. 

28

Table of Contents

Risks Related to the Development and Commercialization of Our Tests and Test Candidates

•Our tests in development may not be clinically effective or may never achieve significant commercial market acceptance and our test offerings that we have recently launched or acquired may not be commercially successful.

•If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our tests, increase our revenue or achieve and sustain profitability.

•If our current research collaborators or scientific advisors terminate their relationships with us or